INT13735

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.42
First Reported 1980
Last Reported 2008
Negated 1
Speculated 0
Reported most in Abstract
Documents 14
Total Number 14
Disease Relevance 4.35
Pain Relevance 5.39

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

extracellular space (GH1) extracellular region (GH1)
Anatomy Link Frequency
plasma 4
PES 2
pituitary 2
somatotroph 2
GH1 (Homo sapiens)
Pain Link Frequency Relevance Heat
Clonidine 31 100.00 Very High Very High Very High
narcan 17 99.76 Very High Very High Very High
Catecholamine 4 98.92 Very High Very High Very High
dopamine receptor 1 98.88 Very High Very High Very High
Somatostatin 31 98.48 Very High Very High Very High
alcohol 1 97.24 Very High Very High Very High
opiate 9 96.96 Very High Very High Very High
antagonist 3 96.88 Very High Very High Very High
noradrenaline 1 95.96 Very High Very High Very High
withdrawal 3 95.80 Very High Very High Very High
Disease Link Frequency Relevance Heat
Acromegaly 32 99.96 Very High Very High Very High
Hypoglycemia 6 99.84 Very High Very High Very High
Chronic Fatigue Syndrome 1 99.76 Very High Very High Very High
Hyponatremia 1 98.96 Very High Very High Very High
Obesity 23 98.40 Very High Very High Very High
Empty Sella Syndrome 8 95.16 Very High Very High Very High
Stress 3 90.64 High High
Depression 2 90.56 High High
Injury 2 90.40 High High
Cyst 1 87.20 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
In contrast, alpha-adrenergic receptor agonism with either propranolol-adrenaline infusion or clonidine increased plasma GH levels at a time when GH responses to this supramaximal dose of GRF were absent.
Negative_regulation (absent) of Regulation (responses) of GH in plasma associated with clonidine
1) Confidence 0.42 Published 1988 Journal Clin. Endocrinol. (Oxf) Section Abstract Doc Link 2855221 Disease Relevance 0 Pain Relevance 0.10
Clonidine administration significantly reduced total catecholamine, pancreatic polypeptide, and prolactin response to 2DG while opiate receptor blockade with naloxone (10 mg IV bolus followed by 2 mg/hr) did not affect catecholamine and pancreatic polypeptide response but did slightly attenuate the GH and PRL response to glucoprivation.
Negative_regulation (attenuate) of Regulation (response) of GH associated with catecholamine, narcan, opiate and clonidine
2) Confidence 0.42 Published 1985 Journal Metab. Clin. Exp. Section Abstract Doc Link 3982277 Disease Relevance 0 Pain Relevance 0.74
DT completely blunted the GH response to ARG, whereas it attenuated the GH response to GAL, but not at a statistically significant level.
Neg (not) Negative_regulation (attenuated) of Regulation (response) of GH
3) Confidence 0.42 Published 1995 Journal Regul. Pept. Section Abstract Doc Link 8570858 Disease Relevance 0 Pain Relevance 0.21
Concerning the influence of metabolic and nutritional factors, an impaired somatotropin response to hypoglycaemia and a failure of glucose load to inhibit spontaneous and stimulated GH release are well documented in obese patients; furthermore, drugs able to block lipolysis and thus to lower serum free fatty acids (NEFA) significantly improve somatotropin secretion in obesity.
Negative_regulation (impaired) of Regulation (response) of somatotropin associated with hypoglycemia and obesity
4) Confidence 0.42 Published 1999 Journal Int. J. Obes. Relat. Metab. Disord. Section Abstract Doc Link 10193871 Disease Relevance 0.95 Pain Relevance 0.08
Before the meal, NAL completely abolished the response of GH to PYR in men (AUC, 1,031.06 +/- 333.21 v 16.50 +/- 7.50 micrograms/L/90 min, P < .01), whereas infusion of NAL did not significantly modify the GH response to PYR in women.
Negative_regulation (abolished) of Regulation (response) of GH associated with narcan
5) Confidence 0.42 Published 1997 Journal Metab. Clin. Exp. Section Abstract Doc Link 9225825 Disease Relevance 0 Pain Relevance 0.50
Conversely, atropine pretreatment significantly (P less than 0.01) blocked the GH response to GHRH challenge, whereas yohimbine did not significantly affect it.
Negative_regulation (blocked) of Regulation (response) of GH
6) Confidence 0.29 Published 1991 Journal J. Clin. Endocrinol. Metab. Section Abstract Doc Link 1677361 Disease Relevance 0 Pain Relevance 0.50
Within the group of normal control subjects, a reduced HGH response was found in most postmenopausal women and in some regular users of alcohol.
Negative_regulation (reduced) of Regulation (response) of HGH associated with alcohol
7) Confidence 0.29 Published 1980 Journal Psychiatry Res Section Abstract Doc Link 6251501 Disease Relevance 0.18 Pain Relevance 0.59
Our data also indicate that GH responses to a GHRH bolus administered 120 min after a prior GHRH challenge are dependent on two parameters: the intrinsic hypothalamic-somatotroph rhythm at the time of the second GHRH bolus, and the magnitude of GH secretion elicited by the previous somatotroph stimulation.
Negative_regulation (administered) of Regulation (responses) of GH in somatotroph
8) Confidence 0.28 Published 1990 Journal J. Clin. Endocrinol. Metab. Section Abstract Doc Link 1977761 Disease Relevance 0 Pain Relevance 0.64
HGH response to clonidine stimulation was only attenuated after 30 days NIC.
Negative_regulation (attenuated) of Regulation (response) of HGH associated with clonidine
9) Confidence 0.25 Published 1986 Journal Pharmacopsychiatry Section Abstract Doc Link 3725889 Disease Relevance 0.22 Pain Relevance 0.27
Presence of normal serum PRL levels, normal PRL response to TRH and reduced GH responses to pituitary and hypothalamic stimuli suggests both hypothalamic and pituitary damage.
Negative_regulation (reduced) of Regulation (responses) of GH in pituitary
10) Confidence 0.21 Published 1996 Journal J. Endocrinol. Invest. Section Abstract Doc Link 8796342 Disease Relevance 0.80 Pain Relevance 0.14
Using IGF-I as primary end-point, 48 weeks lanreotide Autogel treatment, titrated for optimal hormonal control, controlled IGF-I and GH levels effectively, reduced acromegaly symptoms and was well tolerated.



Negative_regulation (reduced) of Regulation (controlled) of GH associated with acromegaly
11) Confidence 0.05 Published 2008 Journal Clinical Endocrinology Section Abstract Doc Link PMC2610402 Disease Relevance 0.26 Pain Relevance 0.05
During hypoglycemia, naloxone infusion reduced plasma PRL levels at 90 min, lowered the overall GH response, and enhanced that of ACTH.
Negative_regulation (lowered) of Regulation (response) of GH in plasma associated with hypoglycemia and narcan
12) Confidence 0.02 Published 1981 Journal J. Clin. Endocrinol. Metab. Section Abstract Doc Link 6263936 Disease Relevance 0.19 Pain Relevance 0.46
The GH response to stimulation was absent (peak:1.0 +/- 0.3 ng/ml) and IGF-I levels (60.1 +/- 9.3 ng/ml) were significantly lower (p<0.001) than in C and group 2 PES patients.
Negative_regulation (absent) of Regulation (response) of GH in PES associated with empty sella syndrome
13) Confidence 0.01 Published 2006 Journal Endocr. J. Section Abstract Doc Link 16983177 Disease Relevance 1.14 Pain Relevance 0.12
An impaired GH response to clonidine and naloxone was found in obese women.
Negative_regulation (impaired) of Regulation (response) of GH associated with obesity, narcan and clonidine
14) Confidence 0.01 Published 1987 Journal Acta Endocrinol. Section Abstract Doc Link 2889310 Disease Relevance 0.61 Pain Relevance 1.00

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox